FILE - In this Friday, June 12, 2020 file photo, a doctor holds a bag of blood plasma donated by a COVID-19 survivor at at blood bank in La Paz, Bolivia. The U.S. Food and Drug Administration authorized the use of blood plasma for what’s called “emergency use” during the coronavirus pandemic, but the World Health Organization (WHO) on Monday AUG. 24, 2020, cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy. (AP Photo/Juan Karita, FILE)

UN cautions that coronavirus plasma treatment still experimental

FDA’s action was announced by U.S. President Donald Trump, who called it a ‘breakthrough’

The World Health Organization on Monday cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy, voicing the concern as a U.S. boost for the treatment has many scientists afraid formal studies will be derailed.

On Sunday, the U.S. Food and Drug Administration authorized what’s called “emergency use” of the treatment under its special powers to speed the availability of promising experimental drugs during a public health crisis. The action isn’t the same as approving plasma as safe and effective, and numerous rigorous studies are underway to find out if it really works.

So far, “The results are not conclusive,” WHO’s chief scientist Dr. Soumya Swaminathan said during a press briefing. “At the moment, it’s still very low-quality evidence.”

Convalescent plasma is a century-old treatment that was used to fight off flu and measles outbreaks in the days before vaccines, and was tried more recently during the Ebola outbreak. When the body encounters a new germ, it makes proteins called antibodies that are specially targeted to fight the infection. The antibodies float in plasma — the yellowish, liquid part of blood — which is collected from COVID-19 survivors and given to patients infected with coronavirus.

Swaminathan said WHO considered plasma therapy to be experimental and that it should continue to be evaluated. She said the treatment is difficult to standardize: Plasma must be collected individually, and people produce different levels of antibodies.

“Of course, countries can do an emergency listing if they feel the benefits outweigh the risks,” she said. “But that’s usually done when you’re waiting for the more definitive evidence.”

READ MORE: Trump announces plasma treatment authorized for COVID-19

In a letter describing the FDA’s emergency action, the agency’s chief scientist said the treatment “should not be considered a new standard of care” for coronavirus infections, and that more data from studies will be available in the coming months.

But already, so many COVID-19 patients have requested plasma rather than agreeing to be part of a research study that many scientists fear they won’t get a clear answer on whether the treatment really works — and if it does, how and when it should be used for the best outcomes.

Martin Landray, of the University of Oxford said that while the therapy offers “huge promise,” there was still no proof it works.

“There is a huge gap between theory and proven benefit,” he said in a statement.

If just a few thousand patients took part in the research “we would have the answer,” said Landray, who is conducting a plasma study in the U.K. “If effective, convalescent plasma could be rapidly used worldwide. If not, it could be abandoned,”

Stephen Griffin, an associate professor of medicine at the University of Leeds, said there was still considerable uncertainty about the immune system’s response to COVID-19, making any potential use of convalescent plasma challenging.

The FDA’s action was announced during a Sunday press briefing by U.S. President Donald Trump, who called it a “breakthrough.”

“It appears that the lessons from hydroxychloroquine have not been learned,” Griffin said, referring to the malaria drug touted by Trump and others as a potential treatment for the coronavirus.

The FDA also granted hydroxychloroquine an emergency authorization before suspending it months later after several trials showed the drug didn’t work against COVID-19 and raised the risk of heart, kidney, liver and other problems.

____

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Maria Cheng, The Associated Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

CoronavirusDonald TrumpUSA

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Unofficial holidays: Here’s what people are celebrating for the week of Sept. 27 to Oct. 3

World Farm Animals Day, Drink Beer Day and Virus Appreciation Day are all coming up this week

NDP candidate Babchuk a fixture in local politics since 2005

School trustee, city councillor and regional district chair sets sights on being North Island MLA

Sointula elementary school gets funding for new playground

Funding for the new playground comes from the provincial government’s Playground Equipment Program.

Facey nominated as BC Liberal candidate for the North Island riding

Liberal candidate Norm Facey has a background in forestry and manufacturing.

Some north Island forest service roads to get a minor facelift with COVID-19 recovery funding

Side Bay access road no longer ‘up in the bureaucratic air’ thanks to temporary budget increase

QUIZ: Do you know what’s on TV?

Fall is normally the time when new television shows are released

Canadian ski resorts wrestle with pandemic-vs.-profit dilemma as COVID-19 persists

Few are actually restricting the total number of skiers they allow on the hill

Victoria-area RCMP locate high-risk sex offender thanks to help of taxi cab driver

Scott Jones wanted on a Canada-wide warrant, ‘a risk to women and girls,’ police say

A (virtual) walk around the world by 88-year-old B.C. man

George Doi says it’s simple: ‘I like walking’

End of CERB means uncertainty for some, new system for others

As of a week ago, the CERB had paid out $79.3 billion to 8.8 million people

Join Black Press Media and Do Some Good

Pay it Forward program supports local businesses in their community giving

Horgan, Wilkinson trade barbs over MSP premiums, health care at campaign stops

Horgan called a snap election for Oct. 24 earlier this week

Most Read